Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1993]

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma ( Dr Martin Hutchings - Copenhagen University Hospital, Copenhagen, Denmark )

Real world evidence on the use of antibody drug conjugates in peripheral T-cell...

Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut...

Real world evidence on the use of antibody drug conjugates in peripheral T-cell lymphoma ( Prof Ali Bazarbachi - American University of Beirut-Medical Center, Beirut, Lebanon )

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP...

Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA

Primary analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML ( Dr Jorge Cortes - Georgia Cancer Center, Augusta, USA )

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in...

Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA

ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up ( Dr Jeff Sharman - Willamette Valley Cancer Institute, Eugene, USA )

CLL14: Venetoclax plus obinutuzumab in untreated CLL

Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany

CLL14: Venetoclax plus obinutuzumab in untreated CLL ( Dr Othman Al-Sawaf - University Hospital of Cologne, Cologne, Germany )

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax...

Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health...

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL ( Dr Rajat Bannerji - Rutgers Cancer Institute of New Jersey/RWJBarnabas Health, New Jersey, USA )

Can multiple endpoints in MM clinical papers create new insights?

Prof Evangelos Terpos and Prof Nina Shah

Can multiple endpoints in MM clinical papers create new insights? ( Prof Evangelos Terpos and Prof Nina Shah )

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in...

Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US

Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma ( Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US )

Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive...

Dr Ryotaro Nakamura - City of Hope, California, USA

Reduced intensity allogeneic HSCT to hypomethylating therapy or best supportive care in older patients with advanced MDS ( Dr Ryotaro Nakamura - City of Hope, California, USA )

OncoAlert and ecancer weekly roundup for February 01 - 06, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for February 01 - 06, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China

Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China

$Emerging treatments for relapsed/refractory Hodgkin’s lymphoma in China ( Dr Qingqing Cai - Sun Yat-Sen University, Guangzhou, China )$

OncoAlert and ecancer weekly roundup for January 11 - 17, 2021

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for January 11 - 17, 2021 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer